Abstract
Germline variation in PTEN results in variable clinical presentations, including benign and malignant neoplasia and neurodevelopmental disorders. Despite decades of research, it remains unclear how PTEN genotype is related to clinical outcomes. In this study, we combined two recent deep mutational scanning (DMS) datasets probing the effects of single-amino acid variation on enzyme activity and steady-state cellular abundance with the largest well-curated clinical cohort of PTEN-variant carriers. We sought to connect variant-specific molecular phenotypes to the clinical outcomes of individuals with PTEN variants. We found that DMS data partially explain quantitative clinical traits, including head circumference and Cleveland Clinic (CC) score, which is a semi-quantitative surrogate of disease burden. We built a logistic regression model using DMS and CADD scores to separate clinical PTEN variation from gnomAD control-only variation with high accuracy (AUC = 0.892). Using a survival-like analysis, we identified molecular phenotype groups with differential risk of early-onset as well as lifetime risk of cancer. Finally, we identified classes of DMS-defined variants with significantly different risk levels for classical hamartoma-related features (odds ratios range of 4.1-102.9). In stark contrast, the risk for developing autism or developmental delay does not significantly change across variant classes (odds ratios range of 5.4-12.4). Together, these findings highlight the potential impact of combining DMS datasets with rich clinical data, and provide new insights that may guide personalized clinical decisions for PTEN-variant carriers.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported, in part, by a NARSAD Young Investigator Grant from the Brain and Behavior Research Foundation through the NARSAD-Atherton Foundation Young Investigator Award (22935 to B. J. O.), a Sloan Research Fellowship in Neurosciences (Alfred P. Sloan Foundation, FG-2015-65608 to B. J. O.), the Ambrose Monell Foundation (to C.E.), the Zacconi Program of PTEN Research Excellence (to C.E.), and internal funds (C.E., B. J. O.). T. L. M received support from the Eunice Kennedy Shriver National Institute of Child Health & Human Development (F31HD095571). T. L. M. is an ARCS scholar (Achievement Rewards for College Scientists Foundation, Inc., Oregon Chapter) and B. J. O. is a Klingenstein-Simons Fellow (Esther A. & Joseph Klingenstein Fund, Simons Foundation). C. E. is the Sondra J. and Stephen R. Hardis Endowed Chair of Cancer Genomic Medicine at the Cleveland Clinic, and is an ACS Clinical Research Professor.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data is available within the manuscript.
